Sutro Biopharma, Inc. (FRA:S090)
Germany
· Delayed Price · Currency is EUR 6.78
-0.41 (-5.70%)
At close: Dec 2, 2025
Sutro Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Revenue | 105.65 | 62.04 | 153.73 | 67.77 | 61.88 | 42.72 | Upgrade
|
| Revenue Growth (YoY) | -34.36% | -59.64% | 126.84% | 9.52% | 44.84% | -0.03% | Upgrade
|
| Cost of Revenue | -38.73 | 12.5 | 11.83 | 10.11 | 104.4 | 76.96 | Upgrade
|
| Gross Profit | 144.37 | 49.54 | 141.9 | 57.67 | -42.52 | -34.24 | Upgrade
|
| Selling, General & Admin | 41.39 | 48.45 | 62.58 | 59.54 | 56 | 36.82 | Upgrade
|
| Research & Development | 239.54 | 239.54 | 168.59 | 127.07 | - | - | Upgrade
|
| Operating Expenses | 280.93 | 287.99 | 231.18 | 186.61 | 56 | 36.82 | Upgrade
|
| Operating Income | -136.55 | -238.45 | -89.28 | -128.94 | -98.52 | -71.06 | Upgrade
|
| Interest Expense | -38.65 | -32.37 | -23.75 | -7.42 | -3.2 | -2.8 | Upgrade
|
| Interest & Investment Income | 12.48 | 18.64 | 14.51 | 3.46 | 0.58 | 1.51 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.67 | -5.06 | - | - | 0.06 | -1.17 | Upgrade
|
| EBT Excluding Unusual Items | -165.4 | -257.24 | -98.52 | -132.91 | -101.08 | -73.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 32.14 | 9.92 | 16.2 | -4.45 | 41.5 | Upgrade
|
| Pretax Income | -214.42 | -225.1 | -88.6 | -116.7 | -105.54 | -32.03 | Upgrade
|
| Income Tax Expense | 2.34 | 2.36 | 18.19 | 2.5 | - | 0.1 | Upgrade
|
| Net Income | -216.77 | -227.46 | -106.79 | -119.2 | -105.54 | -32.13 | Upgrade
|
| Net Income to Common | -216.77 | -227.46 | -106.79 | -119.2 | -105.54 | -32.13 | Upgrade
|
| Shares Outstanding (Basic) | 8 | 8 | 6 | 5 | 5 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 8 | 6 | 5 | 5 | 3 | Upgrade
|
| Shares Change (YoY) | 17.26% | 27.70% | 18.57% | 10.02% | 41.59% | 41.88% | Upgrade
|
| EPS (Basic) | -25.88 | -29.61 | -17.75 | -23.49 | -22.88 | -9.86 | Upgrade
|
| EPS (Diluted) | -25.88 | -29.61 | -17.75 | -23.49 | -22.88 | -9.90 | Upgrade
|
| Free Cash Flow | -225.11 | -194.64 | -115.93 | -4.31 | -97 | -74.93 | Upgrade
|
| Free Cash Flow Per Share | -26.87 | -25.33 | -19.27 | -0.85 | -21.03 | -23.00 | Upgrade
|
| Gross Margin | 136.66% | 79.85% | 92.30% | 85.09% | -68.71% | -80.14% | Upgrade
|
| Operating Margin | -129.25% | -384.33% | -58.07% | -190.26% | -159.22% | -166.32% | Upgrade
|
| Profit Margin | -205.18% | -366.62% | -69.47% | -175.89% | -170.55% | -75.20% | Upgrade
|
| Free Cash Flow Margin | -213.08% | -313.72% | -75.41% | -6.36% | -156.76% | -175.39% | Upgrade
|
| EBITDA | -128.99 | -231.24 | -82.46 | -123.25 | -93.68 | -66.76 | Upgrade
|
| EBITDA Margin | -122.09% | - | -53.64% | -181.86% | -151.39% | -156.27% | Upgrade
|
| D&A For EBITDA | 7.57 | 7.22 | 6.82 | 5.69 | 4.84 | 4.3 | Upgrade
|
| EBIT | -136.55 | -238.45 | -89.28 | -128.94 | -98.52 | -71.06 | Upgrade
|
| EBIT Margin | -129.25% | - | -58.07% | -190.26% | -159.22% | -166.32% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.